Meiji Seika Pharma Co., Ltd.

This study tested two new antibiotic combinations (cefepime/nacubactam and aztreonam/nacubactam) against the best available treatments for adults with serious infections like urinary tract infections, pneumonia, and abdominal infections caused by carbapenem-resistant bacteria. Th…

This phase 3 trial tested two new antibiotic combinations—cefepime/nacubactam and aztreonam/nacubactam—against a standard antibiotic (imipenem/cilastatin) in 614 adults with complicated urinary tract infections or acute kidney infections. The goal was to see if the new combos are…